

## ANGIOGENESIS-BASED CANCER THERAPEUTIC

### SUMMARY

The National Cancer Institute's Urologic Oncology Branch seeks interested parties to co-develop antagonists to VEGF-A and hepatocyte growth factor (HGF) that block signal transduction and associated cellular responses.

### REFERENCE NUMBER

E-230-2011

### PRODUCT TYPE

- Therapeutics

### KEYWORDS

- Chemotherapy
- Macular degeneration
- Diabetic retinopathy
- Angiogenesis
- VEGF-A
- FLT-1
- KDR/FLK-1
- Hepatocyte growth factor (HGF)
- Heparin sulfate proteoglycan

### COLLABORATION OPPORTUNITY

This invention is available for licensing.

### CONTACT

John D. Hewes

NCI - National Cancer Institute

240-276-5515

[John.Hewes@nih.gov](mailto:John.Hewes@nih.gov)

### DESCRIPTION OF TECHNOLOGY

Vascular Endothelial Growth Factor-A (VEGF-A) is an angiogenic agent that drives blood vessel formation in solid tumors and other diseases, such as macular degeneration and diabetic retinopathy. Several therapies that target the ability of VEGF to stimulate angiogenesis have been approved. These therapies regulate VEGF-A activity by binding VEGF-A, thereby blocking VEGF-A from binding to its receptor on target cells. This technology utilizes a different approach to regulating VEGF-A activity by

providing a VEGF-A protein antagonist that is produced by engineering native VEGF-A protein. The engineered VEGF-A protein disrupts heparin sulfate proteoglycan binding to the VEGF-A/VEGF receptor complex, an activity that is essential for the angiogenic properties of native VEGF-A. The antagonist has a binding affinity for both FLT-1 (VEGFR-1) and KDR/FLK-1 (VEGFR-2) that is equivalent to that of native VEGF-A and specifically antagonizes all VEGF-A-stimulated signaling events.

### **POTENTIAL COMMERCIAL APPLICATIONS**

- Therapy for solid tumors or other diseases associated with angiogenic activity modulated by Vascular Endothelial Growth Factor-A expression.

### **COMPETITIVE ADVANTAGES**

- Cost effective in terms of production
- High Specificity/Selectivity

### **INVENTOR(S)**

- [Donald P. Bottaro, PhD](#) (NCI)

### **DEVELOPMENT STAGE**

- Pre-clinical (in vivo)

### **PATENT STATUS**

- **U.S. Filed:** Patent Application 61/639,230 (April 27, 2012)
- **Foreign Filed:** Application No PCT/US2013/03850 (April 26, 2013)

### **THERAPEUTIC AREA**

- Cancer/Neoplasm